Literature DB >> 11563867

Current methods of testing for human papillomavirus.

P Davies1, J Kornegay, T Iftner.   

Abstract

Human papillomavirus DNA testing is gaining wider acceptance, yet the majority of testing is still undertaken in the research setting using protocols that are unsuitable for clinical diagnostic laboratories. Large-scale clinical human papillomavirus DNA testing is likely to be introduced as an adjunct to cervical cytology, so the cytology laboratory is an appropriate place for it to be undertaken. This poses a challenge for any human papillomavirus DNA test since it will be performed by technicians not specifically trained in virology or molecular biology, and will need to produce consistently reliable results in this setting. This is only realistically possible with a standardized and quality-controlled, commercially produced human papillomavirus DNA test. There is currently only one such commercially available assay, although there are a number of research-based tests that could logically lead to additional commercial products. The technological basis of these assays, together with available performance data, is reviewed in this chapter and the clinical utility of the tests is evaluated. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563867     DOI: 10.1053/beog.2001.0214

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  8 in total

1.  Simultaneous amplification and identification of 25 human papillomavirus types with Templex technology.

Authors:  Jian Han; David C Swan; Sharon J Smith; Shanjuan H Lum; Susan E Sefers; Elizabeth R Unger; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2006-09-27       Impact factor: 5.948

2.  Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.

Authors:  Philippe Halfon; Elisabeth Trepo; Gilles Antoniotti; Catherine Bernot; Philippe Cart-Lamy; Hacène Khiri; Didier Thibaud; Jean Marron; Agnès Martineau; Guillaume Pénaranda; Dominique Benmoura; Bernard Blanc
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

Review 3.  Human papillomavirus and cervical cancer: an insight highlighting pathogenesis and targeting strategies.

Authors:  Prachi S Ojha; Meenaxi M Maste; Siddarth Tubachi; Vishal S Patil
Journal:  Virusdisease       Date:  2022-05-30

4.  Performance assessment of eight high-throughput PCR assays for viral load quantitation of oncogenic HPV types.

Authors:  Roberto Flores-Munguia; Erin Siegel; Walter T Klimecki; Anna R Giuliano
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

5.  Biomarkers of cervical dysplasia and carcinoma.

Authors:  Sonya J Hwang; Kenneth R Shroyer
Journal:  J Oncol       Date:  2011-10-29       Impact factor: 4.375

Review 6.  Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer.

Authors:  Maria Lina Tornesello; Luigi Buonaguro; Paolo Giorgi-Rossi; Franco M Buonaguro
Journal:  Biomed Res Int       Date:  2013-12-09       Impact factor: 3.411

7.  Methylation in the promoter regions of WT1, NKX6-1 and DBC1 genes in cervical cancer tissues of Uygur women in Xinjiang.

Authors:  Dan Wu; Jinli Zhang; Peiwen Fan; Hongtao Li; Dongmei Li; Huan Pan; Hongchang He; Xianxian Ren; Zhenzhen Pan; Renfu Shao; Zemin Pan
Journal:  Genet Mol Biol       Date:  2018 Jan-Mar       Impact factor: 1.771

8.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.

Authors:  G M Clifford; J S Smith; M Plummer; N Muñoz; S Franceschi
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.